With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
Today on Living Oklahoma we were joined by Rebecca Jones.She spoke to Matt Stafford about here journey with Alzheimer's and ...
McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...
Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...
Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...
STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback